Chevy Chase Trust Holdings LLC Has $44.36 Million Holdings in Illumina, Inc. $ILMN

Chevy Chase Trust Holdings LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 464,979 shares of the life sciences company’s stock after selling 60,685 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.29% of Illumina worth $44,364,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Sage Private Wealth Group LLC raised its holdings in Illumina by 79.5% during the 2nd quarter. Sage Private Wealth Group LLC now owns 6,649 shares of the life sciences company’s stock worth $634,000 after buying an additional 2,945 shares during the period. Nordea Investment Management AB grew its stake in Illumina by 14.2% during the 2nd quarter. Nordea Investment Management AB now owns 13,138 shares of the life sciences company’s stock valued at $1,265,000 after acquiring an additional 1,633 shares in the last quarter. WCM Investment Management LLC grew its stake in Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after acquiring an additional 247,460 shares in the last quarter. Wilmington Savings Fund Society FSB grew its stake in Illumina by 36.6% during the 2nd quarter. Wilmington Savings Fund Society FSB now owns 8,194 shares of the life sciences company’s stock valued at $782,000 after acquiring an additional 2,194 shares in the last quarter. Finally, RFG Advisory LLC grew its stake in Illumina by 39.1% during the 2nd quarter. RFG Advisory LLC now owns 5,411 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 1,520 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ILMN. Canaccord Genuity Group lifted their target price on Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Barclays lifted their target price on Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research note on Thursday, October 2nd. Finally, Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price on the stock. in a research note on Friday, July 11th. Five equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $115.25.

Illumina Trading Down 0.5%

Shares of NASDAQ ILMN opened at $95.46 on Friday. The stock has a market cap of $14.67 billion, a price-to-earnings ratio of 12.08, a PEG ratio of 2.32 and a beta of 1.40. The business has a 50 day simple moving average of $98.12 and a 200 day simple moving average of $90.68. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.